Bicara Therapeutics (NASDAQ:BCAX) Announces Quarterly Earnings Results, Misses Expectations By $0.22 EPS

Key Points

• Bicara Therapeutics reported a quarterly loss of $1.04 per share, missing analyst expectations of a $0.82 loss by $0.22.
• The stock opened at $8.65, near its one-year low of $7.87; its market capitalization was about $572 million.
• Analyst views are mixed: the consensus rating is “Moderate Buy” with a $30.91 target price, though Goldman Sachs downgraded the stock to sell and cut its target to $8.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) posted its quarterly earnings data on Monday. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.22), FiscalAI reports.

Bicara Therapeutics Stock Performance

Shares of Bicara Therapeutics stock opened at $8.65 on Monday. The business's 50 day moving average price is $18.16 and its 200 day moving average price is $20.95. The company has a market cap of $572.40 million, a price-to-earnings ratio of -2.79 and a beta of -0.33. Bicara Therapeutics has a one year low of $7.87 and a one year high of $30.99.

Analyst Ratings Changes

Several analysts recently commented on BCAX shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Bicara Therapeutics in a research report on Friday, October 2nd. The Goldman Sachs Group cut shares of Bicara Therapeutics from a "neutral" rating to a "sell" rating and lowered their target price for the stock from $20.00 to $8.00 in a research note on Friday, October 30th. BTIG Research reaffirmed a "buy" rating and set a $39.00 target price on shares of Bicara Therapeutics in a report on Monday, October 19th. Wedbush reduced their target price on shares of Bicara Therapeutics from $33.00 to $24.00 and set an "outperform" rating for the company in a research report on Thursday, October 29th. Finally, BMO Capital Markets initiated coverage on shares of Bicara Therapeutics in a research report on Tuesday, August 18th. They issued an "outperform" rating and a $35.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $30.91.

Insider Transactions at Bicara Therapeutics

In other news, CEO Ryan Cohlhepp sold 17,500 shares of Bicara Therapeutics stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $22.90, for a total transaction of $400,750.00. Following the transaction, the chief executive officer owned 181,641 shares in the company, valued at $4,159,578.90. The trade was a 8.79% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.80% of the stock is currently owned by insiders.

About Bicara Therapeutics

Bicara Therapeutics Inc is a clinical-stage biotechnology company developing bifunctional therapies for the treatment of solid tumors. The company's approach is designed to combine tumor-targeting activity with immune-system modulation in a single therapeutic candidate.

Bicara's lead product candidate is ficerafusp alfa, also known as BCA101. The investigational therapy is designed to target epidermal growth factor receptor (EGFR) on cancer cells while simultaneously trapping transforming growth factor beta (TGF-β), a signaling protein that can contribute to tumor growth and immune suppression.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.